# Society for Immunotherapy of Cancer

Source: https://onco.cc/institutions/sitc/  
OnCo record `sitc` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The society of cancer immunologists and immuno-oncologists, whose annual meeting, guidelines and immune-related adverse event management resources track the immunotherapy era.

## Summary

Founded in 1984 as the Society for Biological Therapy and renamed in 2010, SITC grew with checkpoint inhibitors into the main professional home of cancer immunotherapy. Its annual meeting each November presents cellular therapy, checkpoint, vaccine and bispecific data and translational immunology; it publishes the Journal for ImmunoTherapy of Cancer, issues Cancer Immunotherapy Guidelines by disease and on immune-related toxicities, and runs the Immuno-Oncology Biomarkers task forces, the Sparkathon early-career programme and the SITC Cancer Immunotherapy Winter School. SITC also produces the primer on CAR-T toxicity management and works with FDA on regulatory science for immunotherapy combinations.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: SITC; International Society for Biological Therapy of Cancer; iSBTc
- City: Milwaukee, WI, US
- Type: consortium
- Website: https://www.sitcancer.org

## Sources

- SITC: https://www.sitcancer.org
- Guidelines: https://www.sitcancer.org/research/cancer-immunotherapy-guidelines

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- institutions: [American Association for Cancer Research (AACR)](https://onco.cc/institutions/aacr/), [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/), [Moffitt Cancer Center](https://onco.cc/institutions/moffitt/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)
- people: [Drew M. Pardoll](https://onco.cc/people/drew-pardoll/), [F. Stephen Hodi](https://onco.cc/people/f-stephen-hodi/), [Howard L. Kaufman](https://onco.cc/people/howard-kaufman/), [Jason J. Luke](https://onco.cc/people/jason-luke/), [Patrick Hwu](https://onco.cc/people/patrick-hwu/), [Sandra Demaria](https://onco.cc/people/sandra-demaria/), [Suzanne L. Topalian](https://onco.cc/people/suzanne-topalian/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/)
- journals: [Journal for ImmunoTherapy of Cancer](https://onco.cc/journals/jitc/)

---
JSON: https://onco.cc/api/v1/entities/sitc.json